Body fat has stronger associations with bone mass density than body mass index in metabolically healthy obesity

Yuan-Yuei Chen¹,², Wen-Hui Fang², Chung-Ching Wang², Tung-Wei Kao²,³,⁴, Yaw-Wen Chang²,³, Chen-Jung Wu²,³,⁵, Yi-Chao Zhou², Yu-Shan Sun²,³, Wei-Liang Chen²,³⁎

¹ Department of Internal Medicine, Tri-Service General Hospital Songshan Branch, Tri-Service General Hospital; School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China, ² Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital; and School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China, ³ Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital; and School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China, ⁴ Graduate Institute of Clinical Medical, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China, ⁵ Division of Family Medicine, Department of Community Medicine, Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan, Republic of China

* weiliang0508@gmail.com

Abstract

Objective

The effect of obesity-induced metabolic abnormalities on bone mineral density (BMD) and osteoporosis are well established. However, the association between metabolically healthy obesity (MHO) and BMD remains unclear. Our aim was to investigate whether different obesity phenotypes in MHO were associated with BMD in a cross-sectional study.

Methods

All eligible adults receiving a health examination at the Tri-Service General Hospital from 2010 to 2016 were included. They were categorized based on body mass index (BMI) or percentage body fat (PBF). The associations between BMI or PBF and BMD were analyzed by adjusting for pertinent covariables.

Results

Males with normal weight and overweight and females with underweight and normal weight were associated with reduced BMD (β = 0.221, 95%CI = -0.354, -0.088; β = -0.155, 95% CI = -0.286, -0.023) (β = -0.736, 95%CI = -1.043, 0.429; β = -0.340, 95%CI = -0.567, -0.112), respectively. Females in Q1 had close to significant associations with reduced BMD (β = -0.253, 95%CI = -0.465, -0.041). Normal weight, overweight, Q2, and Q3 had stronger prediction of low BMD with ORs of 0.402 (95%CI = 0.204–0.791), 0.539 (95%CI = 0.321–0.905), 0.694 (95%CI = 0.490–0.982), and 0.466 (95%CI = 0.342–0.636), respectively. The relationship remained significant in male population that PBF was associated with reduced BMD with ORs of 0.435 (95%CI = 0.203, 0.935), 0.494 (95%CI = 0.247, 0.991), 0.268 (95%CI = 0.120, 0.597) in Q1, Q2, Q3 respectively.
Conclusion
Increased PBF had a significant association with low BMD in the MHO population. Obesity defined by PBF might be a useful indicator for low BMD. The association between body fat and bone health deserves further investigation regarding the potential pathophysiological mechanisms.

Introduction
Osteoporosis, diagnosed by measurement of bone mineral density (BMD), is a common health problem worldwide due to its high risk for fractures, morbidity and mortality and expensive health care costs[1]. Impacts on BMD are caused by a multifactorial etiology, including metabolic syndrome (MetS) and obesity. Accumulated evidence indicates significant associations between osteoporosis and metabolic abnormalities such as central obesity, hypertension, hyperglycemia and dyslipidemia [2–4]. It is well established that low body mass is correlated with reduced BMD and an increased risk of osteoporosis. However, controversial studies have indicated that increased percentage body fat (PBF) and abdominal fat accumulation are strongly associated with low BMD[5, 6].

Sarcopenic obesity, defined as low muscle mass and the presence of obesity, has been reported to be associated with an increased risk of osteoporosis and non-vertebral fracture[7]. Sarcopenic obesity has also been suggested to be associated with low BMD in the elderly population[8]. Metabolically healthy obesity (MHO), a condition observed in a subgroup of obese individuals who do not display MetS, was recently reported in several studies[9, 10]. People with MHO are prevalent and are generally agreed to comprise up to 25%, but not more than 30%, of the adult obese population[11, 12]. It was proposed that those with MHO had lower risks of cardiovascular diseases and preserved insulin sensitivity[13]. However, unlike the relationship of obesity and BMD, the potential association between MHO and BMD is largely unexplored. The aim of our study was to investigate whether having MHO individuals was associated with BMD in a cross-sectional study composed of participants receiving a health examination at the Tri-Service General Hospital (TSGH) in Taiwan.

Methods
Study design
This cross-sectional study was composed of male and female participants aged 20 years old and older who underwent comprehensive health examinations in the TSGH. Study approval was given by the Institutional Review Board of Tri-Service General Hospital, Taiwan. The Institutional Review Board waived the requirement for individual informed consent because the data were analyzed anonymously. MHO is defined as a specific feature of obesity that is not accompanied by MetS. Exclusion criteria of our study were chronic liver diseases, inflammatory bowel disease, chronic kidney disease, cancer, lupus, multiple myeloma, rheumatoid arthritis, thyroid disorders, and missing information (including baseline characteristics, and dual energy x-ray absorptiometry (DEXA)) (N = 56178). Additionally, those with MetS as defined by the Taiwan Health Promotion Administration of the Ministry of Health and Welfare in 2007 were also excluded (N = 6269).[14]. In the final analysis, there were 6776 metabolically healthy participants. For body mass index (BMI), we divided all eligible subjects into 4 categories: (1) underweight: BMI<18.5 (N = 380); (2) normal weight: 18.5<BMI<24
(N = 3747); (3) overweight: 24 < \text{BMI} < 27 (N = 1841); and (4) obese: BMI > 27 (N = 797). Obesity was defined as a BMI > 27 kg/m² according to the criteria of the Department of Health in Taiwan [15]. For PBF, the study sample was divided again into 4 categories by classifying the PBF values of subjects in quartiles: (1) Q1: PBF < 22.8 (N = 1565); (2) Q2: 22.8 < PBF < 27.2 (N = 1541); (3) Q3: 27.2 < PBF < 32.4 (N = 1522); and (4) Q4: PBF > 32 (N = 1532).

**Measurement of BMD**

DEXA, the most frequently used technique for measuring BMD, was performed during the health examinations by using a Prodigy Series X-Ray Tube Housing Assembly (GE Medical Systems Lunar 3030 Ohmeda Dr Madison, Wisconsin, USA). DEXA can be applied to measure BMD at various body sites. The density of the lumbar spine was measured rather than the total hip. We excluded those participants with past histories of vertebral fracture, vertebroplasty, or implants of polymethylmethacrylate cement.

**Diagnosis of low BMD and osteoporosis**

Lumbar spine osteoporosis and low BMD were defined in the health examinations based on the criteria of the World Health Organization [16]. The definition of osteoporosis was a BMD less than or equal to 2.5 SDs below that of a young, healthy adult female reference group [17]. Low BMD was diagnosed when the lumbar spine BMD value was between -1 and -2.5 SDs below that of the young reference group.

**Measurement of PBF**

PBF was the indicator used in the study and was measured by BIA (InBody720, Biospace, Inc., Cerritos, CA, USA), which was non-invasive, portable, and inexpensive. This accurate technique is effective and has been validated to estimate body composition parameters such as total body weight, extracellular water, intracellular water, and fat mass [18].

**Definition of MetS**

MetS was diagnosed if an individual had ≥3 of the following characteristics based on the Taiwan Health Promotion Administration of the Ministry of Health and Welfare in 2007 [14]: (1) waist circumference (WC): male > 90 cm and female > 80 cm; (2) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 80 mmHg, or self-reported hypertension; (3) triglyceride (TG) ≥ 150 mg/dL (1.7 mmol/L); (4) fasting plasma glucose (FPG) ≥ 100 mg/dL, or a past history of diabetes status; and (5) high density lipoprotein cholesterol (HDL-C): male < 40 mg/dL (1.03 mmol/L) and female < 50 mg/dL (1.3 mmol/L).

**Covariate measurements**

BMI was estimated based on a general formula where the weight of the individual in kilograms was divided by the square of the individual’s height in meters (kg/m²). Biochemical data were collected by drawing blood samples from subjects after fasting for at least 8 hours; the samples were measured by standard procedures. Data on cigarette smoking were obtained from participants by asking the question “How many packs do you smoke per day”. Consumption of alcohol was determined by self-report questionnaire, and participants were divided into “never” and “alcohol consumption” groups. Proteinuria was measured in a random urine sample during the health examination and in a first morning void urine sample collected by the participant. Proteinuria was diagnosed by dipstick test, which is a basic diagnostic tool for determining pathological changes in urine sample in standard urinalysis [19].
Statistical analysis
Statistical estimations used in the study were performed using the Statistical Package for the Social Sciences, version 18.0 (SPSS Inc., Chicago, IL, USA) for Windows. The differences between males and females in terms of demographic information and biochemical data were examined by Student’s t and Pearson’s chi-square tests. A two-sided p-value of ≤ 0.05 was regarded as the threshold for statistical significance. An extend-model approach was used with multivariable adjustment for pertinent clinical variables as follows: Model 1 = age + gender; Model 2 = Model 1 + proteinuria, total cholesterol (TC), uric acid (UA), creatinine (Cr), aspartate transaminase (AST), albumin, high sensitivity C-reactive protein (hsCRP), and thyroid stimulating hormone (TSH); and Model 3 = Model 2 + history of cigarette smoking and alcohol consumption. Natural logarithm transformation was performed to normalize the distributions of all variables before analysis because variables were nonlinearly related to the response variable. Linear regression was performed to assess the association between different obesity phenotypes and BMD. Logistic regression was used to investigate gender differences in the associations between different obesity phenotypes and the presence of low BMD and osteoporosis.

Results
Epidemiological characteristics
Table 1 shows the characteristics of participants categorized by BMI (underweight: BMI <18.5; normal weight: 18.5 ≤ BMI <24; overweight: 24 ≤ BMI <27; obese: BMI ≥ 27) or PBF (Q1: PBF <22.8; Q2: 22.8 ≤ PBF <27.2; Q3: 27.2 ≤ PBF <32.4; Q4: PBF ≥ 32.4). The mean ages of the underweight, normal weight, overweight, and obese BMI subgroups were 42.48 ± 13.55, 48.00 ± 12.41, 51.01 ± 11.95, and 49.00 ± 12.47 years, respectively. The mean ages of the Q1, Q2, Q3, and Q4 PBF subgroups were 46.80 ± 12.62, 49.48 ± 12.00, 49.44 ± 11.74, and 52.18 ± 12.48 years, respectively. The percentages of males in each BMI subgroup were 21.2% (underweight), 44.6% (normal weight), 72.7% (overweight), and 72.5% (obese). In the PBF subgroups, the percentages of males were Q1: 85.4%, Q2: 67.5%, Q3: 40.3%, and Q4: 17.1%. All continuous variables, smoking history and alcohol consumption were significantly different among the BMI subgroups (P <0.05). By contrast, all continuous variables except AST, and smoking history and alcohol consumption were significantly different among the PBF subgroups (P <0.05).

Associations between different obesity phenotypes and BMD
Table 2 shows the associations between different obesity phenotypes and BMD by gender. In males, being of normal weight and being overweight were associated with reduced BMD with β values of -0.221 (95%CI = -0.354, -0.088) and -0.155 (95%CI = -0.286, -0.023), respectively. However, no significant difference was observed between PBF and BMD. In the female population, being of underweight and being normal weight were significantly associated with reduced BMD with β values of -0.736 (95%CI = -1.043, 0.429) and -0.340 (95%CI = -0.567, -0.112), respectively. Being in Q1 was related to reduced BMD with a β value of -0.253 (95%CI = -0.465, -0.041).

Associations between different obesity phenotypes and the presence of low BMD and osteoporosis
Table 3 shows odd ratios (ORs) of different obesity phenotypes for predicting the presence of low BMD and osteoporosis as obtained by multivariable logistic regression. Being of normal weight and overweight could predict the presence of low BMD with ORs of 0.402 (95% CI = 0.204, 0.791) and 0.539 (95%CI = 0.321, 0.905), respectively. Being in Q2 and Q3 were
associated with low BMD with ORs of 0.694 (95%CI = 0.490, 0.982) and 0.466 (95%CI = 0.342, 0.636), respectively, in the fully adjusted model. However, no significant differences were noted among the associations with osteoporosis in the study sample.

The results based on gender differences are demonstrated in Table 4. There were no significant findings regarding different obesity phenotypes and low BMD in the female population. On the contrary, male subjects displayed the same results as described above. ORs were 0.279 (95%CI = 0.104, 0.750) and 0.360 (95%CI = 0.170, 0.760) in the normal weight and overweight groups, respectively, and 0.435 (95%CI = 0.203, 0.935), 0.494 (95%CI = 0.247, 0.991), and 0.268 (95%CI = 0.120, 0.597) in Q1, Q2, and Q3, respectively.

Table 1. Characteristics of study sample.

| Variables | BMI<18.5 Underweight | 18.5<BMI<24 Normal weight | 24<BMI<27 Overweight | BMI>27 Obese | P Value |
|-----------|----------------------|---------------------------|---------------------|--------------|--------|
| BMD       | -0.30 (1.60)         | -0.20 (1.70)              | 0.60 (1.90)         | 0.80 (1.70)  | <0.001 |
| Age       | 45.27 (22.58)        | 50.72 (17.35)             | 52.92 (16.09)       | 51.12 (18.09)| <0.001 |
| TC        | 184.00 (43.00)       | 189.00 (48.00)            | 190.00 (47.00)      | 191.00 (49.00)| <0.001 |
| UA        | 4.30 (1.30)          | 5.10 (1.80)               | 6.10 (1.80)         | 6.40 (2.10)  | <0.001 |
| Cr        | 0.70 (0.00)          | 0.80 (0.00)               | 0.90 (0.00)         | 0.90 (0.00)  | <0.001 |
| AST       | 18.00 (7.00)         | 19.00 (7.00)              | 20.00 (7.00)        | 21.00 (9.00) | <0.001 |
| Albumin   | 4.50 (0.00)          | 4.50 (0.00)               | 4.50 (0.00)         | 4.50 (0.00)  | <0.001 |
| hsCRP     | 0.04 (0.00)          | 0.07 (0.00)               | 0.11 (0.00)         | 0.20 (0.00)  | <0.001 |
| TSH       | 2.07 (2.00)          | 1.98 (1.00)               | 1.86 (1.00)         | 1.99 (2.00)  | 0.003  |

Table 2. Characteristics of study sample (male).

| Variables | PBF<22.8 Q1 | 22.8<PBF<27.2 Q2 | 27.2<PBF<32.4 Q3 | PBF>32.4 Q4 | P Value |
|-----------|-------------|------------------|------------------|-------------|--------|
| BMD       | 0.50 (1.80) | 0.40 (1.80)      | 0.40 (1.70)      | 0.20 (2.00) | <0.001 |
| Age       | 48.56 (18.72)| 51.12 (16.98)   | 51.05 (16.03)    | 53.26 (16.32)| <0.001 |
| TC        | 184.00 (46.00)| 191 (50.00)     | 188.00 (45.00)   | 196.00 (47.00)| <0.001 |
| UA        | 5.80 (1.60) | 5.80 (2.20)      | 5.10 (2.20)      | 5.20 (1.80)  | <0.001 |
| Cr        | 0.90 (0.00) | 0.90 (0.00)      | 0.70 (0.00)      | 0.70 (0.00)  | <0.001 |
| AST       | 19.00 (7.00) | 19.00 (8.00)     | 19.00 (7.00)     | 19.00 (8.00) | 0.114  |
| Albumin   | 4.50 (0.00) | 4.50 (0.00)      | 4.50 (0.00)      | 4.40 (0.00)  | <0.001 |
| hsCRP     | 0.06 (0.00) | 0.08 (0.00)      | 0.09 (0.00)      | 0.15 (0.00)  | <0.001 |
| TSH       | 1.85 (1.00) | 1.90 (1.00)      | 1.96 (1.00)      | 2.14 (2.00)  | <0.001 |

IQR, inter quartile range; BMD, bone mineral density; TC, total cholesterol; UA, uric acid; Cr, creatinine; AST, aspartate transaminase; hsCRP, high sensitive C-reactive protein; TSH, thyroid stimulating hormone.

https://doi.org/10.1371/journal.pone.0206812.t001
In the present study, we highlighted the associations between different obesity phenotypes and bone mass density (BMD) in an MHO population from a large population-based survey. We observed that obesity as defined by BMI was closely associated with increased BMD, and that obesity as defined by percent body fat (PBF) was related to reduced BMD. Not only BMI but also PBF had a likelihood of predicting the presence of low BMD, particularly in the male population. To the best of our knowledge, our study is the first to explore the associations between different obesity phenotypes and low BMD and osteoporosis in an adult population.

Controversial findings have been reported in several studies on the impact of obesity on bone metabolism. Obesity has conventionally been suggested to be beneficial to bones and protective against osteoporosis [20]. Salamat et al. reported that obesity, defined by BMI, conferred a reduced risk for osteoporosis and low BMD in a non-institutionalized population [21]. Body fat and lean mass were suggested to contribute to the maintenance of BMD, by generating a mechanical overload on the bones [22, 23]. However, recent evidence has shown that excess body fat might not have a beneficial effect on BMD [24]. Sarcopenic obesity, a specific term for the presence of decreased muscle mass and increased body fat, was reported to be associated with the development of osteoporosis among an elderly population [7, 8]. A similar result was presented by Zhao et al., who reported that fat mass was inversely correlated with bone mass genetically, environmentally, and phenotypically [25]. In a Korean study, BMI was considered as a protective factor against vertebral fractures and was related to increased BMD; however, PBF was a risk factor for vertebral fractures and low BMD [26]. A recent study with Pacific Island women showed that PBF was inversely associated with BMD [27]. Accumulated visceral adipose tissue was associated with low BMD in middle-aged Chinese women [28]. This is consistent with our findings that increased PBF values had a harmful effect on bone health and could predict the risk of developing low BMD. Although positive relationship with BMD

### Table 2. Association between different obesity phenotypes and BMD in gender difference.

| Gender | BMI/PBF groups          | Model *1  | P Value | Model *2  | P Value | Model *3  | P Value |
|--------|-------------------------|-----------|---------|-----------|---------|-----------|---------|
|        | BMD                     | β* (95% CI)|         | β* (95% CI)|         | β* (95% CI)|         |
| Male   | Underweight vs Obese   | -0.658 (-1.256, -0.061) | 0.031 | -0.552 (-1.156, 0.051) | 0.073 | -0.560 (-1.163, 0.044) | 0.069 |
|        | Normal weight vs Obese | -0.246 (-0.376, -0.116) | <0.001 | -0.222 (-0.355, -0.089) | <0.001 | -0.221 (-0.354, -0.088) | <0.001 |
|        | Overweight vs Obese    | -0.167 (-0.299, -0.036) | 0.012 | -0.153 (-0.285, -0.022) | 0.022 | -0.155 (-0.286, -0.023) | 0.023 |
|        | Q1 vs Q4                | 0.033 (-0.137, 0.204) | 0.701 | 0.053 (-0.121, 0.227) | 0.551 | 0.062 (-0.113, 0.236) | 0.489 |
|        | Q2 vs Q4                | 0.069 (-0.103, 0.242) | 0.429 | 0.084 (-0.089, 0.257) | 0.343 | 0.088 (-0.085, 0.261) | 0.318 |
|        | Q3 vs Q4                | 0.059 (-0.122, 0.241) | 0.523 | 0.077 (-0.105, 0.259) | 0.405 | 0.083 (-0.099, 0.265) | 0.370 |
| Female | Underweight vs Obese   | -0.747 (-1.047, -0.447) | <0.001 | -0.736 (-1.043, -0.429) | <0.001 | -0.736 (-1.043, 0.429) | <0.001 |
|        | Normal weight vs Obese | -0.350 (-0.572, -0.127) | 0.002 | -0.345 (-0.572, -0.117) | 0.003 | -0.340 (-0.567, -0.112) | 0.003 |
|        | Overweight vs Obese    | -0.035 (-0.287, 0.216) | 0.782 | -0.026 (-0.279, 0.227) | 0.838 | -0.025 (-0.279, 0.228) | 0.845 |
|        | Q1 vs Q4                | -0.211 (-0.417, -0.005) | 0.045 | -0.255 (-0.466, -0.044) | 0.018 | -0.253 (-0.465, -0.041) | 0.019 |
|        | Q2 vs Q4                | -0.125 (-0.287, 0.036) | 0.127 | -0.140 (-0.306, 0.026) | 0.098 | -0.131 (-0.297, 0.035) | 0.122 |
|        | Q3 vs Q4                | -0.106 (-0.237, 0.025) | 0.112 | -0.105 (-0.239, 0.028) | 0.122 | -0.103 (-0.236, 0.031) | 0.132 |

* Adjusted covariates:
  Model 1 = age
  Model 2 = Model 1 + proteinuria, TC, UA, Cr, AST, albumin, hsCRP, TSH
  Model 3 = Model 2 + history of smoking, drinking

β* was interpreted as change of BMD for each increase in obesity phenotypes

https://doi.org/10.1371/journal.pone.0206812.t002

**Discussion**

In the present study, we highlighted the associations between different obesity phenotypes and BMD in an MHO population from a large population-based survey. We observed that obesity as defined by BMI was closely associated with increased BMD, and that obesity as defined by PBF was related to reduced BMD. Not only BMI but also PBF had a likelihood of predicting the presence of low BMD, particularly in the male population. To the best of our knowledge, our study is the first to explore the associations between different obesity phenotypes and low BMD and osteoporosis in an adult population.

Controversial findings have been reported in several studies on the impact of obesity on bone metabolism. Obesity has conventionally been suggested to be beneficial to bones and protective against osteoporosis [20]. Salamat et al. reported that obesity, defined by BMI, conferred a reduced risk for osteoporosis and low BMD in a non-institutionalized population [21]. Body fat and lean mass were suggested to contribute to the maintenance of BMD, by generating a mechanical overload on the bones [22, 23]. However, recent evidence has shown that excess body fat might not have a beneficial effect on BMD [24]. Sarcopenic obesity, a specific term for the presence of decreased muscle mass and increased body fat, was reported to be associated with the development of osteoporosis among an elderly population [7, 8]. A similar result was presented by Zhao et al., who reported that fat mass was inversely correlated with bone mass genetically, environmentally, and phenotypically [25]. In a Korean study, BMI was considered as a protective factor against vertebral fractures and was related to increased BMD; however, PBF was a risk factor for vertebral fractures and low BMD [26]. A recent study with Pacific Island women showed that PBF was inversely associated with BMD [27]. Accumulated visceral adipose tissue was associated with low BMD in middle-aged Chinese women [28]. This is consistent with our findings that increased PBF values had a harmful effect on bone health and could predict the risk of developing low BMD. Although positive relationship with BMD...
has been reported in previous studies, higher BMI had a tendency to predict a risk of lower BMD in our study. The underlying mechanism for this observation was unclear. In a cross-sectional study including women of different ethnicities, higher BMI caused increased BMD for white women while it reduced BMD in African Americans[29]. It appears that there is a race-dependent effect of obesity on BMD.

Several experimental and clinical studies have suggested that obesity is detrimental to bone health. Proinflammatory cytokines such as TNF-α, IL-1, and IL-6, which are induced by adipose tissues, contribute to the development of osteoclast activity and bone resorption[30]. The stimulating mechanism of osteoclasts was via the regulation of RANKL/RANK/OPG[31]. Adipogenesis might be a plausible pathway for the impact of obesity on reduced bone formation, because adipocytes and osteoblasts originate from common multi-potential mesenchymal stem cells[32]. In obese animal models, altered bone metabolism might result from the overproduction of leptin[33]. Increased secretion of leptin or decreased production of adiponectin could result in macrophages accumulation induced by adipocytes[34].

A gender difference in the association between obesity with BMD was observed in our study based on our finding that only among male subjects did obesity have tendency for predicting the presence of low BMD. Because the study sample of health examinations was derived from an adult population, most female individuals had not experienced the dramatic drop in circulating estradiol levels that accompanies menopause. A previous study reported

| Variable | Model 1 OR (95% CI) | P Value | Model 2 OR (95% CI) | P Value | Model 3 OR (95% CI) | P Value |
|----------|----------------------|---------|----------------------|---------|----------------------|---------|
| **BMI**  |                       |         |                       |         |                       |         |
| Obese    | Reference             | -       | Reference             | -       | Reference             | -       |
| Overweight| 1.358 (0.889–2.704)   | 0.157   | 0.533 (0.318–0.895)   | 0.017   | 0.539 (0.321–0.905)   | 0.019   |
| Normal weight | 2.310 (1.566–3.408)  | <0.001  | 0.399 (0.203–0.785)   | 0.008   | 0.402 (0.204–0.791)   | 0.008   |
| Underweight | 5.064 (3.168–8.097) | <0.001  | 0.530 (0.202–1.389)   | 0.196   | 0.533 (0.203–1.399)   | 0.201   |
| **PBF**  |                       |         |                       |         |                       |         |
| Q4       | Reference             | -       | Reference             | -       | Reference             | -       |
| Q3       | 0.511 (0.395–0.661)   | <0.001  | 0.466 (0.342–0.636)   | <0.001  | 0.466 (0.342–0.636)   | <0.001  |
| Q2       | 0.606 (0.473–0.775)   | <0.001  | 0.693 (0.490–0.980)   | 0.038   | 0.694 (0.490–0.982)   | 0.039   |
| Q1       | 0.629 (0.493–0.803)   | <0.001  | 0.764 (0.500–1.168)   | 0.215   | 0.761 (0.498–1.163)   | 0.207   |
| **Osteoporosis** |                       |         |                       |         |                       |         |
| Obese    | Reference             | -       | Reference             | -       | Reference             | -       |
| Overweight | 2.132 (0.471–9.661)  | 0.326   | 0.441 (0.079–2.454)   | 0.350   | 0.450 (0.081–2.499)   | 0.361   |
| Normal weight | 3.427 (0.823–14.271)| 0.091   | 0.126 (0.015–1.083)   | 0.059   | 0.124 (0.014–1.070)   | 0.058   |
| Underweight | 16.523 (3.782–72.182)| <0.001  | 0.185 (0.012–2.915)   | 0.230   | 0.179 (0.011–2.823)   | 0.221   |
| PBF      |                       |         |                       |         |                       |         |
| Q4       | Reference             | -       | Reference             | -       | Reference             | -       |
| Q3       | 0.561 (0.288–1.091)   | 0.088   | 0.555 (0.255–1.208)   | 0.138   | 0.562 (0.257–1.226)   | 0.148   |
| Q2       | 0.433 (0.211–0.888)   | 0.022   | 0.623 (0.248–1.564)   | 0.313   | 0.623 (0.247–1.573)   | 0.317   |
| Q1       | 0.709 (0.382–1.315)   | 0.275   | 1.109 (0.391–3.144)   | 0.846   | 1.122 (0.395–3.192)   | 0.829   |

* Adjusted covariates: Model 1 = age Model 2 = Model 1 + proteinuria, TC, UA, Cr, AST, albumin, hsCRP, TSH Model 3 = Model 2 + history of smoking, drinking

https://doi.org/10.1371/journal.pone.0206812.t003
that significant changes of hormones in women were believed to be the major cause of rapid bone loss in women during menopause[35]. Estrogen inhibited bone resorption by inducing cumulative changes in multiple estrogen-dependent regulatory factors to affect osteoclast formation[36]. The protective role of sex hormones appeared to be a plausible explanation for the varying results regarding BMD by gender.

There were several limitations to the present study. First, the sample analyzed in our study was composed of a relatively healthy general adult population. Participants with osteoporosis were rare and not prevalent in this age group. It was not surprising that no significant differences were observed in the associations between obesity phenotypes and the presence of osteoporosis. Second, the dataset was derived from an exclusively Asian population, so the limited ethnic diversity of the participants might not reflect the racial differences that exist for the association of obesity with BMD. Next, this was a cross-sectional design, so causal inferences are not able to be made; a longitudinal survey is suggested for use in further studies. Finally, various factors can limit the use of BIA. Relative increases in extracellular water and total body water might underestimate the percentage of body fat and overestimate fat-free mass in the obese state[18]. Food intake can lower the results of body fat measurements by causing a variation between the highest and lowest PBF readings of PBF[37]. Overestimation of fat mass and underestimation of PBF are observed after moderate exercise due to reduced impedance[38].

### Table 4. Association between different obesity phenotypes with the presence of low BMD in sex difference.

| Sex | Variables | Model *1 OR (95% CI) | P Value | Model *2 OR (95% CI) | P Value | Model *3 OR (95% CI) | P Value |
|-----|-----------|----------------------|---------|----------------------|---------|----------------------|---------|
| Male | BMI       |                      |         |                      |         |                      |         |
|      | Obese     | Reference            | -       | Reference            | -       | Reference            | -       |
|      | Overweight| 1.309 (0.693–2.473)  | 0.407   | 0.361 (0.171–0.762)  | 0.008   | 0.360 (0.170–0.760)  | 0.007   |
|      | Normal weight | 3.127 (1.739–5.623) | <0.001 | 0.282 (0.105–0.757)  | 0.012   | 0.279 (0.104–0.750)  | 0.111   |
|      | Underweight| 13.656 (6.173–30.213)| <0.001 | 0.304 (0.066–1.405)  | 0.127   | 0.294 (0.063–1.366)  | 0.118   |
|      | PBF       |                      |         |                      |         |                      |         |
|      | Q4        | Reference            | -       | Reference            | -       | Reference            | -       |
|      | Q3        | 0.506 (0.238–1.076)  | 0.077   | 0.271 (0.122–0.604)  | <0.001  | 0.268 (0.120–0.597)  | <0.001  |
|      | Q2        | 1.229 (0.659–2.291)  | 0.514   | 0.498 (0.249–0.997)  | 0.049   | 0.494 (0.247–0.991)  | 0.047   |
|      | Q1        | 1.763 (0.967–3.213)  | 0.064   | 0.437 (0.204–0.938)  | 0.034   | 0.435 (0.203–0.935)  | 0.033   |
| Female| BMI      |                      |         |                      |         |                      |         |
|       | Obese     | Reference            | -       | Reference            | -       | Reference            | -       |
|       | Overweight| 1.314 (0.729–2.370)  | 0.364   | 0.735 (0.338–1.599)  | 0.438   | 0.763 (0.351–1.661)  | 0.496   |
|       | Normal weight | 1.125 (0.657–1.928) | 0.686   | 0.420 (0.154–1.143)  | 0.090   | 0.436 (0.160–1.188)  | 0.104   |
|       | Underweight| 1.797 (0.969–3.333) | 0.063   | 0.657 (0.168–2.566)  | 0.545   | 0.686 (0.175–2.686)  | 0.589   |
|       | PBF       |                      |         |                      |         |                      |         |
|       | Q4        | Reference            | -       | Reference            | -       | Reference            | -       |
|       | Q3        | 0.670 (0.506–0.888)  | 0.005   | 0.695 (0.478–1.010)  | 0.057   | 0.694 (0.477–1.009)  | 0.056   |
|       | Q2        | 0.904 (0.655–1.247)  | 0.537   | 1.123 (0.702–1.797)  | 0.629   | 1.122 (0.701–1.797)  | 0.631   |
|       | Q1        | 0.680 (0.429–1.076)  | 0.099   | 0.671 (0.351–1.285)  | 0.229   | 0.654 (0.342–1.253)  | 0.201   |

* Adjusted covariates:
  Model 1 = age
  Model 2 = Model 1 + proteinuria, TC, UA, Cr, AST, albumin, hsCRP, TSH
  Model 3 = Model 2 + history of smoking, drinking

[https://doi.org/10.1371/journal.pone.0206812.t004](https://doi.org/10.1371/journal.pone.0206812.t004)
Conclusion

Our findings demonstrated that increased PBF was significantly associated with reduced BMD after adjusting for variable confounders in an MHO sample and that high PBF might be a useful indicator for low BMD. A gender difference was noted, indicating that hormones might be a key factor influencing bone metabolism. The association between body fat and bone health deserves further investigation into the potential pathophysiological mechanisms. Strategies for preventing the detrimental impact of obesity and prolonged follow-up research for predicting risks of incident low BMD and even osteoporosis are necessary.

Author Contributions

Conceptualization: Wei-Liang Chen.

Data curation: Yuan-Yuei Chen, Wen-Hui Fang, Chung-Ching Wang, Tung-Wei Kao, Yaw-Wen Chang, Chen-Jung Wu, Yi-Chao Zhou, Yu-Shan Sun, Wei-Liang Chen.

Formal analysis: Yuan-Yuei Chen, Wen-Hui Fang, Chung-Ching Wang, Tung-Wei Kao, Yaw-Wen Chang, Chen-Jung Wu, Yi-Chao Zhou, Yu-Shan Sun, Wei-Liang Chen.

Investigation: Yuan-Yuei Chen, Wen-Hui Fang, Chung-Ching Wang, Tung-Wei Kao, Yaw-Wen Chang, Chen-Jung Wu, Yi-Chao Zhou, Yu-Shan Sun, Wei-Liang Chen.

Methodology: Yuan-Yuei Chen, Wen-Hui Fang, Chung-Ching Wang, Tung-Wei Kao, Yaw-Wen Chang, Chen-Jung Wu, Yi-Chao Zhou, Yu-Shan Sun, Wei-Liang Chen.

Project administration: Yuan-Yuei Chen, Wei-Liang Chen.

Supervision: Wei-Liang Chen.

Validation: Yuan-Yuei Chen, Wei-Liang Chen.

Visualization: Yuan-Yuei Chen, Wei-Liang Chen.

Writing – original draft: Yuan-Yuei Chen.

Writing – review & editing: Yuan-Yuei Chen, Wei-Liang Chen.

References

1. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Jama. 2009; 301(5):513–21. Epub 2009/02/05. https://doi.org/10.1001/jama.2009.50 PMID: 19190316.

2. Yuksel O, Dokmetas HS, Topcu S, Erselecan T, Sencan M. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. Journal of bone and mineral metabolism. 2001; 19(4):257–62. Epub 2001/07/13. PMID: 11448019.

3. Varenna M, Manara M, Galli L, Binelli L, Zucchi F, Sinigaglia L. The association between osteoporosis and hypertension: the role of a low dairy intake. Calcified tissue international. 2013; 93(1):86–92. Epub 2013/05/09. https://doi.org/10.1007/s00223-013-9731-9 PMID: 23652773.

4. Muka T, Trajanoska K, Kieffte-de Jong JC, Oei L, Uitterlinden AG, Hofman A, et al. The Association between Metabolic Syndrome, Bone Mineral Density, Hip Bone Geometry and Fracture Risk: The Rotterdam Study. PLoS ONE. 2015; 10(6):e0129116. https://doi.org/10.1371/journal.pone.0129116 PubMed PMID: PMC4466576. PMID: 26066649

5. Jeon YK, Lee JG, Kim SS, Kim BH, Kim SJ, Kim YK, et al. Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women. Endocrine journal. 2011; 58(2):87–93. Epub 2011/01/19. PMID: 21242648.

6. Chain A, Crivelli M, Faerstein E, Bezerra FF. Association between fat mass and bone mineral density among Brazilian women differs by menopausal status: The Pro-Saude Study. Nutrition (Burbank, Los Angeles County, Calif). 2017; 33:14–9. Epub 2016/12/03. https://doi.org/10.1016/j.nut.2016.08.001 PMID: 27908545.
Association between metabolically healthy obesity and bone mass density

7. Scott D, Chandrasekara SD, Laslett LL, Cicuttini F, Ebeling PR, Jones G. Associations of Sarcopenic Obesity and Dynapenic Obesity with Bone Mineral Density and Incident Fractures Over 5–10 Years in Community-Dwelling Older Adults. Calcified tissue international. 2016; 99(1):30–42. Epub 2016/03/05. https://doi.org/10.1007/s00223-016-0123-9 PMID: 26939775.

8. Chung JH, Hwang HJ, Shin HY, Han CH. Association between Sarcopenic Obesity and Bone Mineral Density in Middle-Aged and Elderly Korean. Annals of nutrition & metabolism. 2016; 68(2):77–84. Epub 2015/12/08. https://doi.org/10.1159/000442004 PMID: 26640893.

9. Phillips CM. Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. Annals of the New York Academy of Sciences. 2017; 1391(1):85–100. Epub 2016/10/11. https://doi.org/10.1111/nyas.13230 PMID: 27723940.

10. van Vliet-Oostapchouk JV, Nuotio M-L, Slagter SN, Doiron D, Fischer K, Foco L, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocrine Disorders. 2014; 14(1):9. https://doi.org/10.1186/1472-6823-14-9 PMID: 24484869.

11. Lee K. Metabolically obese but normal weight (MONW) and metabolically healthy but obese (MHO) phenotypes in Koreans: characteristics and health behaviors. Asia Pacific Journal of clinical nutrition. 2009; 18(2):280–4. Epub 2009/08/29. PMID: 19713189.

12. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragogna F, Villa M, et al. Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian Individuals. The Cremona Study. 2011; 34(1):210–5. https://doi.org/10.2337/dc10-0665 PMID: 20937689.

13. Stefan N, Haring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. The lancet Diabetes & endocrinology. 2013; 1(2):152–62. Epub 2014/03/14. https://doi.org/10.1016/s2213-8587(13)70062-7 PMID: 24622321.

14. National Department of Health. The Definition of the Metabolic Syndrome in Adults. 2007. Available from: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=639&pid=1219.

15. Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi. 2006; 105(8):626–35. Epub 2006/08/29. https://doi.org/10.1016/S0929-6646(06)01613-3 PMID: 16935763.

16. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. Journal of bone and mineral research; the official journal of the American Society for Bone and Mineral Research. 1994; 9(8):1137–41. Epub 1994/08/01. https://doi.org/10.1002/jbmr.5650090802 PMID: 7976495.

17. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. Journal of clinical densitometry: the official journal of the International Society for Clinical Densitometry. 2013; 16(4):455–66. Epub 2013/11/05. https://doi.org/10.1016/j.jcd.2013.09.003 PMID: 24189389.

18. Coppini LZ, Waitzberg DL, Campos AC. Limitations and validation of bioelectrical impedance analysis in morbidly obese patients. Current opinion in clinical nutrition and metabolic care. 2005; 8(3):329–32. Epub 2005/04/06. PMID: 15809537.

19. Yetisen AK, Akram MS, Lowe CR. Paper-based microfluidic point-of-care diagnostic devices. Lab on a Chip. 2013; 13(12):2210. https://doi.org/10.1039/c3lc50169h PMID: 23652632.

20. Villareal DT, Apovian CM, Kushner RF, Klein S. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAAASO, The Obesity Society. The American journal of clinical nutrition. 2005; 82(5):923–34. Epub 2005/11/11. https://doi.org/10.1093/ajcn/82.5.923 PMID: 16280421.

21. Salamat MR, Salamat AH, Janghborhani M. Association between Obesity and Bone Mineral Density by Gender and Menopausal Status. Endocrinology and Metabolism. 2016; 31(4):547–58. https://doi.org/10.3803/EnM.2016.31.4.547 PubMed PMID: PMCS195832. PMID: 27834082.

22. Kaji H. Linkage between muscle and bone: common catabolic signals resulting in osteoporosis and sarcopenia. Current opinion in clinical nutrition and metabolic care. 2013; 16(3):272–7. Epub 2013/03/14. https://doi.org/10.1097/MCO.Ob013e32835f6f45 PMID: 23481148.

23. Bhupathiraju SN, Dawson-Hughes B, Hannan MT, Lichtenstein AH, Tucker KL. Centrally located body fat is associated with lower bone mineral density in older Puerto Rican adults. The American journal of clinical nutrition. 2011; 94(4):1063–70. Epub 2011/09/26. https://doi.org/10.3945/ajcn.111.016030 PMID: 21865328; PubMed Central PMCID: PMCPMC3173024.

24. Janicka A, Wren TA, Sanchez MM, Dorey F, Kim PS, Mittelman SD, et al. Fat mass is not beneficial to bone in adolescents and young adults. The Journal of clinical endocrinology and metabolism. 2007; 92(1):143–7. Epub 2006/10/19. https://doi.org/10.1210/jc.2006-0794 PMID: 17047019.
25. Zhao L-J, Liu Y-J, Liu P-Y, Hamilton J, Recker RR, Deng H-W. Relationship of obesity with osteoporosis. The Journal of clinical endocrinology and metabolism. 2007; 92(5):1640–6. https://doi.org/10.1210/jc.2006-0572 PubMed PMID: PMC1868430. PMID: 17299077

26. Kim K-C, Shin D-H, Lee S-Y, Im J-A, Lee D-C. Relation between Obesity and Bone Mineral Density and Vertebral Fractures in Korean Postmenopausal Women. Yonsei Medical Journal. 2010; 51(6):857–63. https://doi.org/10.3349/yjm.2010.51.6.857 PubMed PMID: PMC2995981. PMID: 20879051

27. Casale M, von Hurst PR, Beck KL, Shultz S, Kruger MC, O’Brien W, et al. Lean Mass and Body Fat Percentage Are Contradictory Predictors of Bone Mineral Density in Pre-Menopausal Pacific Island Women. Nutrients. 2016; 8(8):470. https://doi.org/10.3390/nu8080470 PubMed PMID: PMC4997383. PMID: 27483314

28. Wang L, Wang W, Xu L, Cheng X, Ma Y, Liu D, et al. Relation of visceral and subcutaneous adipose tissue to bone mineral density in chinese women. International journal of endocrinology. 2013; 2013:378632. Epub 2013/07/19. https://doi.org/10.1155/2013/378632 PubMed PMID: 23861681; PubMed Central PMCID: PMCPMC3686129.

29. Castro JP, Joseph LA, Shin JJ, Arora SK, Nicasio J, Shatzkes J, et al. Differential effect of obesity on bone mineral density in White, Hispanic and African American women: a cross sectional study. Nutrition & Metabolism. 2005; 2(1):9. https://doi.org/10.1186/1743-7075-2-9 PMID: 15817133

30. Cao JJ. Effects of obesity on bone metabolism. Journal of Orthopaedic Surgery and Research. 2011; 6:30-. https://doi.org/10.1186/1749-799X-6-30 PubMed PMID: PMC3141563. PMID: 21676245

31. Pfleischlatter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocrine reviews. 2002; 23(1):90–119. Epub 2002/02/15. https://doi.org/10.1210/edrv.23.1.0456 PMID: 11844745.

32. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nature clinical practice Rheumatology. 2006; 2(1):35–43. Epub 2006/08/26. https://doi.org/10.1038/ncprheum0070 PMID: 16932650.

33. Cao JJ, Sun L, Gao H. Diet-induced obesity alters bone remodeling leading to decreased femoral trabecular bone mass in mice. Annals of the New York Academy of Sciences. 2010; 1192:292–7. Epub 2010/04/16. https://doi.org/10.1111/j.1749-6632.2009.05252.x PMID: 20392249.

34. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. Science (New York, NY). 1998; 281(5383):1683–6. Epub 1998/09/11. PMID: 9735517.

35. Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone. 1996; 19(1):9–12. Epub 1996/07/01. PMID: 8830981.

36. Riggs BL. The mechanisms of estrogen regulation of bone resorption. Journal of Clinical Investigation. 2000; 106(10):1203–4. PubMed PMID: PMC381441. https://doi.org/10.1172/JCI11468 PMID: 11088020

37. Slinde F, Rossander-Hulthen L. Bioelectrical impedance: effect of 3 identical meals on diurnal impedance variation and calculation of body composition. The American journal of clinical nutrition. 2001; 74(4):474–8. Epub 2001/09/22. https://doi.org/10.1093/ajcn/74.4.474 PMID: 11566645.

38. Kushner RF, Gudvika R, Schoeller DA. Clinical characteristics influencing bioelectrical impedance analysis measurements. The American journal of clinical nutrition. 1996; 64(3 Suppl):423s–7s. Epub 1996/09/01. https://doi.org/10.1093/ajcn/64.3.423S PMID: 8780398.